Figure 1
Cisplatin-resistant gastric cancer cell models display higher motility.
(A) Cell growth curve of cisplatin-resistant MGC803 and AGS cells, versus parental MGC803 and AGS cells. Values represented the mean ± SD from two independent experiments with triplicate samples. DDP, cisplatin. (B) IC50 and RI for DDP in drug resistant and parental gastric cancer cells. Values represented the mean ± SD from three independent experiments with triplicate samples. RI, resistance index. (C) Cisplatin-resistant gastric cancer cells exhibit higher wound healing ability. Photos were taken at 0 and 24 h after wounding. (D) Summary of wound healing assays. Results were presented as the mean ± SD of two independent experiments, **P < 0.01 compared with parental cells. (E) Cisplatin-resistant gastric cancer cells possess higher cell migratory capacity in vitro. The results were mean ± SD of three independent experiments with triplicate wells. **P < 0.01.
